ShanghaiNovember 30, 2022/ PR Newswire /-- recently, Frost & Sullivan, an authoritative international consultancy, announced the results of the 2022 Best practice Award (Frost & Sullivan Best Practices Awards). Wuxi Apptec won the "2022 Global CRDMO Company of the year Award" for his industry-leading omni-directional, integrated new drug R & D and production enabling platform. This is the sixth year in a row that Wuxi Apptec has been recognized by the agency.
Frost Sullivan's Best practice Award recognizes companies around the world that are at the forefront of innovation and growth and continue to provide innovative solutions and outstanding services to their customers. Frost Sullivan believes that Wuxi Apptec is committed to meeting the changing needs of the pharmaceutical and health industry. With its strong leadership, Frost Sullivan has created excellent customer value and become a model for best practice companies. Wuxi Apptec has an integrated and omni-directional enabling platform, and through its unique CRDMO and CTDMO business models, it has become a trusted partner for customers around the world, constantly helping customers to promote the research and development of innovative drugs for the benefit of patients around the world.
"Wuxi Apptec's unique business model covers the entire value chain of new drug research and development," said Unmesh Lal, director of healthcare and life sciences at Frost Sullivan. "in addition, Wuxi Apptec continues to build capacity and scale in new molecules and innovative therapies such as targeted protein degradation, oligonucleotides, peptides, antibody-coupled drugs, cell and gene therapy (CGT), to better empower customers to accelerate the process of new drug research and development."
"Wuxi Apptec is honored to receive the 2022 Global CRDMO Company of the year Award and thanks Frost Sullivan for the value that the company's enabling platform creates for customers and the pharmaceutical and health industry." Dr. Li GE, Chairman and CEO of Wuxi Apptec, said, "We will continue to strengthen our capacity and scale to help global partners accelerate the process of new drug research and development and promote the early launch of more breakthrough treatment solutions to benefit patients around the world."
About Wuxi Apptec
Wuxi Apptec (Stock Code: 603259.SH/2359.HK) provides integrated, end-to-end new drug R & D and production services for the global biomedical industry, with operating bases in Asia, Europe and North America. Through its unique "CRDMO" and "CTDMO" business models, Wuxi Apptec continues to lower the R & D threshold, help customers improve R & D efficiency, and bring more breakthrough treatment solutions to patients, covering chemical drug R & D and production, biological research, preclinical and clinical trial R & D, cellular and gene therapy R & D, testing and production. In 2022, Wuxi Apptec was rated ESG (Environment, Society and Governance) AA by MSCI. At present, the company's enabling platform is carrying the R & D and innovation projects of more than 5900 partners from more than 30 countries around the world, committed to bringing more new and good drugs to patients around the world, and realizing as soon as possible "so that there are no difficult drugs in the world." the vision of an intractable disease.